| Person |
Company |
Title |
| Tanja D. de Gruijl, Ph.D. |
Vrije Universiteit medisch centrum, the Netherlands |
T Lymphocyte and Dendritic Cell (DC) Function in Patients with Metastatic Hormone-Refractory Prostate Cancer Treated with a GM-CSF-Transduced Allogeneic Prostate Cancer Vaccine and Anti-CTLA-4 Antibody |
| Samuel R. Denmeade, M.D. |
The Johns Hopkins School of Medicine |
Validation of the Role of PSA Inhibitors in Preventing the Development, Growth and Metastasis of Prostate Cancer |
| Phillip Febbo, M.D. |
Duke Institute for Genome Sciences and Policy |
Feasibility of Detecting Expression Signatures for Docetaxel Response in Prostate Cancer |
| Stephen J. Freedland, M.D. |
The Johns Hopkins School of Medicine |
Role of a Ketogenic in Prostate Cancer Growth and Progression |
| Michael E. Jung, Ph.D. |
University of California, Los Angeles |
Synthesis and Testing of New Selective Androgen Receptor Antagonists |
| Richard P. Junghans, M.D., Ph.D. |
Roger Williams Medical Center |
Advanced Generation Therapies of Anti-PSMA Designer T Cells for Prostate Cancer |
| Michael Karin, Ph.D. |
University of California, San Diego |
Role of IKK/NF-kB Signaling in Development of Androgen-Independent Prostate Cancer |
| Clara L. Kielkopf, Ph.D. |
The Johns Hopkins University |
Structural Mechanisms of Small Molecule MBD2-Antagonists for Prostate Cancer Therapy |
| Dolores J. Lamb, Ph.D. |
Baylor College of Medicine |
Emodin: a Potent Inhibitor of Prostate Cancer Growth |
| Sue-Hwa Lin, Ph.D. |
The University of Texas M. D. Anderson Cancer Center |
Bone Metastasis Factor-1 (MDA-BF-1) for Predicting the Emergence of Bone Metastasis |
| Massimo Loda, M.D. |
Dana Farber Cancer Institute |
Fatty Acid Synthase as a Metabolic Oncogene in Prostate Cancer |
| Valeri V. Mossine, Ph.D. |
University of Missouri-Columbia |
Prevention and Treatment of Prostate Cancer with Dietary Ketosamine Antioxidants |
| Nora M. Navone, M.D., Ph.D. |
The University of Texas M. D. Anderson Cancer Center |
Role of Wnt Signaling in the Pathophysiology of Prostate Cancer Bone Metastasis |
| Renata Pasqualini, Ph.D. |
The University of Texas M. D. Anderson Cancer Center |
Targeting the Interleukin 11 Receptor in Prostate Cancer Metastasis |
| Amnon Peled, Ph.D. |
Hadassah University Hospital, Israel |
Treatment of Prostate Tumor Growth, Vascularization and Metastasis in Vivo Using the CXCR4 Antagonists T140 and AMD3100 |
| Roberto Pili, M.D. |
The Johns Hopkins University |
HDAC6 as a Target for Antiangiogenesis Therapy in Prostate Cancer |
| Yun Qiu, Ph.D. |
University of Maryland School of Medicine |
Regulation of Androgen Receptor Activity by Tyrosine Phosphorylation in Hormone Refractory Prostate Cancer |
| Neal Rosen, M.D., Ph.D. |
Memorial Sloan-Kettering Cancer Center |
Development of Therapeutic Strategies for the Inhibition of PI3 Kinase-Mediated Signaling Pathways in Advanced Prostate Cancer |
| Howard I. Scher, M.D. |
Memorial Sloan-Kettering Cancer Center |
Preclinical and Clinical Studies in Prostate Specific PTEN-p53 Conditional Knockout Mice and In Man |
| Meir J. Stampfer, M.D., Sc.D. |
Harvard School of Public Health |
Selenium and the Manganese Superoxide Dismutase (MnSOD) Polymorphism in Prostate Cancer Survival |
| Dean G. Tang, M.D., Ph.D. |
The University of Texas M. D. Anderson Cancer Center |
Prostate Cancer Stem Cells: Identification, Characterization, and Their Role in Prostate Tumorigenesis |
| Shaomeng Wang, Ph.D. |
University of Michigan Comprehensive Cancer Center |
Design and Testing of Highly Potent Small-Molecule Inhibitors of Bcl-2 for the Treatment of Hormone-Refractory Prostate Cancer |
| Michael J. Weber, Ph.D. |
University of Virginia Health System |
Preclinical Studies on a new MEK Inhibitor in Advanced Prostate Cancer |
| George Wilding, M.D. |
University of Wisconsin Comprehensive Cancer Center |
Pentamethylchromanol as a New Therapeutic Antiandrogen for Prostate Cancer |
| Owen N. Witte, M.D. |
Howard Hughes Medical Institute/UCLA |
Characterization of Prostate Cancer Stem Cells by Tissue Regeneration |
